KNOREX LTD. Class A Ordinary Shares (KNRX)

Dallas TX - Sept. 28, 2026 - From AI data centers and Alzheimer’s research to drug safety testing and humanoid robots, six small-cap companies are approaching developments that could shape their next phase of growth.

Dallas TX - Sept. 28, 2026 - VivoSim Labs Inc. (NASDAQ: VIVS) is developing human-relevant testing technologies designed to identify unsuccessful drug candidates earlier, potentially improving the economics of pharmaceutical development.

Dallas TX - Sept. 28, 2026 - American Fusion Inc. (OTCQB: AMFN) has filed 21 additional U.S. patent applications, bringing its Texatron™ intellectual-property portfolio to 151 pending U.S. applications, as the company continues testing its fusion-energy platform and prepares for a potential national-exchange listing.

KNOREX Ltd. (“KNOREX” or the “Company”; NYSE American: KNRX), a leading provider of AI-driven cross-channel programmatic advertising solutions, today announced that it is pursuing a strategic carve-out of AscendX Media Technologies Pte. Ltd. (“AscendX”), its wholly owned publisher monetization subsidiary. Under the proposed structure, AscendX would be separated and independently capitalized with investment from external investors, and KNOREX expects to retain a minority equity interest in AscendX.

KNOREX, Ltd. ("KNOREX"; NYSE American: KNRX), a leading provider of AI-driven cross-channel programmatic advertising execution solutions, today announced the launch of KAI Assistsm within its flagship advertising management execution platform, KNOREX XPO. With complete rollout by the end of this month, KAI Assist introduces a conversational, natural language interface designed to streamline end-to-end digital advertising workflows—from campaign creation and audience targeting to real-time optimization.

KNOREX Ltd. (NYSE American: KNRX) (“KNOREX” or the “Company”), a leading provider of AI-driven cross-channel advertising technology solutions, today announced that it received a notice (the "Notice") on August 21, 2026, from the NYSE American LLC ("NYSE American") stating that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(i) and (ii) of the NYSE American Company Guide (the "Company Guide").

KNOREX Ltd. (NYSE American: KNRX) (“KNOREX” or the “Company”), a leading provider of AI-driven cross-channel advertising technology solutions, today advised that its Financial Statements included in its Annual Report on Form 20F for the year ended December 31, 2025, contained an audit report from its Independent Registered Public Accounting Firm with an explanatory paragraph emphasizing that the Consolidated Financial Statements were prepared assuming that the Company will continue as a going concern. Release of this information is required by Section 610(b) of the NYSE American Company Guide and does not reflect any change or amendment to any of the Company’s filings for the fiscal year ended December 31, 2025.

KNOREX Ltd. (NYSE American: KNRX) (“KNOREX” or the “Company”), a leading provider of AI-driven cross-channel advertising technology solutions, today provided a business update and reported financial results for the fiscal year ended December 31, 2025. The Company previously disclosed that it required additional time to complete its year-end reporting process following its transition to a U.S. public company. The 20-F filing has now been completed and is available on the SEC's website at www.sec.gov.

Artificial Intelligence is rapidly transforming drug discovery, clinical research , and Alzheimer's disease development, and IGC Pharma, Inc. (NYSE: IGC) is positioning itself at the forefront of that evolution. The clinical-stage biotechnology company will present seven scientific papers at the Alzheimer's Association International Conference (AAIC) 2026 in London, July 12-15, highlighting a growing portfolio of AI-powered healthcare technologies designed to accelerate Alzheimer's drug development , improve clinical trials , and enhance precision medicine .